cryptophycin-52 and Adenocarcinoma

cryptophycin-52 has been researched along with Adenocarcinoma* in 1 studies

Other Studies

1 other study(ies) available for cryptophycin-52 and Adenocarcinoma

Article	Year
A convergent approach to cryptophycin 52 analogues: synthesis and biological evaluation of a novel series of fragment a epoxides and chlorohydrins. Journal of medicinal chemistry, 2003, Jul-03, Volume: 46, Issue:14 Cryptophycin 52 is a synthetic derivative of Cryptophycin 1, a potent antimicrotubule agent isolated from cyanobacteria. In an effort to increase the potency and water solubility of the molecule, a structure-activity relationship study (SAR) was initiated around the phenyl ring of fragment A. These Cryptophycin 52 analogues were accessed using a Wittig olefination reaction between various triphenylphosphonium salts and a key intermediate aldehyde prepared from Cryptophycin 53. Substitution on the phenyl ring of fragment A was well tolerated, and several of these analogues were equally or more potent than Cryptophycin 52 when evaluated in vitro in the CCRF-CEM leukemia cell line and in vivo against a murine pancreatic adenocarcinoma. Topics: Adenocarcinoma; Animals; Antineoplastic Agents; Depsipeptides; Drug Screening Assays, Antitumor; Humans; Lactams; Lactones; Male; Mice; Neoplasm Transplantation; Pancreatic Neoplasms; Structure-Activity Relationship; Tumor Cells, Cultured	2003

Article

Year

A convergent approach to cryptophycin 52 analogues: synthesis and biological evaluation of a novel series of fragment a epoxides and chlorohydrins.

Journal of medicinal chemistry, 2003, Jul-03, Volume: 46, Issue:14

Cryptophycin 52 is a synthetic derivative of Cryptophycin 1, a potent antimicrotubule agent isolated from cyanobacteria. In an effort to increase the potency and water solubility of the molecule, a structure-activity relationship study (SAR) was initiated around the phenyl ring of fragment A. These Cryptophycin 52 analogues were accessed using a Wittig olefination reaction between various triphenylphosphonium salts and a key intermediate aldehyde prepared from Cryptophycin 53. Substitution on the phenyl ring of fragment A was well tolerated, and several of these analogues were equally or more potent than Cryptophycin 52 when evaluated in vitro in the CCRF-CEM leukemia cell line and in vivo against a murine pancreatic adenocarcinoma.

Topics: Adenocarcinoma; Animals; Antineoplastic Agents; Depsipeptides; Drug Screening Assays, Antitumor; Humans; Lactams; Lactones; Male; Mice; Neoplasm Transplantation; Pancreatic Neoplasms; Structure-Activity Relationship; Tumor Cells, Cultured

2003